SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
Notification of Late Filing
Commission File Number: 0-15888
(Check one)
[x] Form 10-K or 10-KSB [ ] Form 20-F [ ] Form 11-K
[ ] Form 10-Q or 10-QSB [ ] Form 10-D [ ] Form N-SAR
[ ] Form N-CSR
For period ended December 31, 2007
_________________
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the transition period ended _______________
Nothing in this form shall be construed to imply that the Commission
has verified any information contained herein.
If the notification relates to a portion of the filing checked
above, identify the item(s) to which the notification relates:
PART I
REGISTRANT INFORMATION
Full name of registrant: IGENE Biotechnology, Inc.
_________________________
Former name if applicable:
Address of principal executive office (Street and Number):
9110 Red Branch Road
____________________
City, State and Zip Code:
Columbia, Maryland 21045
_________________________
Page 1
PART II
RULE 12B-25(b) AND (c)
If the subject report could not be filed without unreasonable
effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if appropriate.)
(a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
(b) The subject annual report, semi-annual report, transition report on
Form 10-K, Form 20-F, Form 11-K, Form N-SAR, or Form N-CSR, or
portion thereof, will be filed on or before the fifteenth calendar
[x] day following the prescribed due date; or the subject quarterly
report or transition report on Form 10-Q or subject distribution
report on Form 10-D, or portion thereof, will be filed on or before
the fifth calendar day following the prescribed due date; and
(c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
PART III
NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-
SAR, N-CSR, or the transition report or portion thereof could not be filed
within the prescribed time period. (Attach extra sheets if needed.)
Although the Company's management has been working diligently to complete
all the required information for the Company's annual report on Form 10-KSB
for the year ended December 31, 2007, and a substantial part of such
information has been completed as of this date, the Company and its
auditors are unable, without unreasonable effort or expense, to complete
the financial statements and other disclosures for the Form 10-KSB on or
before March 31, 2008. The delays in the filing are related to the
resolution of an accounting issue discussed with the Securities and
Exchange Commission. Management expects to file its annual report on Form
10-KSB on or before April 15, 2008.
PART IV
OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification.
Edward J. Weisberger
(410) 997-2599
(2) Have all other periodic reports required under Section 13 or
15(d) or the Securities Exchange Act of 1934 or Section 30 of the
Investment Company Act of 1940 during the preceding 12 months (or for such
shorter period) that the registrant was required to file such report(s)
been filed? If the answer is no, identify report(s).
[x] Yes [ ] No
(3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report
or portion thereof?
[ ] Yes [x] No
If so, attach an explanation of the anticipate change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
Page 2
IGENE Biotechnology, Inc.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: March 31, 2008 By: /S/ EDWARD J. WEISBERGER
________________________________
EDWARD J. WEISBERGER
Chief Financial Officer
Page 3